info@marketresearchfuture.com   📞  +1 (855) 661-4441(US)   📞  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Global Juvenile Macular Degeneration (Stargardt Disease) Market Research Report Information by Diagnosis (Fluorescein Angiography and others), Management (Magnifying Spectacles and others), End User (Hospital & Eye Clinics and others) and Region - Forecast till 2032


ID: MRFR/Pharma/3504-CR | 119 Pages | Author: Rahul Gotadki| July 2019

Juvenile Macular Degeneration Market Overview :


Juvenile Macular Degeneration (Stargardt Disease) Market Size was valued at USD 1.44 Billion in 2023. The Global Juvenile Macular Degeneration (Stargardt Disease) industry is projected to grow from USD 1.52 Billion in 2024 to USD 1.85 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.36% during the forecast period (2024 - 2032).


Juvenile macular degeneration is a genetic eye disorder that causes progressive vision loss. This disorder affects the retina, the specialized light-sensitive tissue that lines the back of the eye. Specifically, juvenile macular degeneration affects a small area near the center of the retina called the macula. The macula is responsible for sharp central vision, which is needed for detailed tasks such as reading, driving, and recognizing faces. The market is mainly driven by factors such as the increasing prevalence of eye disorders, development of new drugs and therapies, and emerging government policies. However, the high cost of treatment and lack of reimbursement is expected to restrain the growth of this market.


Market Dynamics


The rising prevalence of eye disorder and technological advancements in juvenile macular degeneration are some of the factors that drive the growth of the market. Juvenile macular degeneration is a rare inherited eye condition which affects the central area of the retina called the macula, also known as fundus flavimaculatus. It affects about 1 in 10,000 people and is sometimes called juvenile macular dystrophy since it tends to first appear between the ages of 10 to 20 although visual impairment may not be apparent until as late as ages 30 to 40. Juvenile macular degeneration disease causes parts of the macula to stop working, leading to problems with central vision, detailed vision, and sometimes with color perception. The major driving factors for the global juvenile macular degeneration market are increasing the prevalence of eye disorders, development of new drugs, and therapies, and emerging government policies. However, lack of awareness and no treatment option for juvenile macular dystrophy may hamper the market growth.


Global Juvenile Macular Degeneration (Stargardt Disease) Market Size, by Diagnosis, 2016 and 2027 (USD Million)  Juvenile Macular Degeneration (Stargardt Disease) Market


Source: MRFR Analysis


Segmentation


The global juvenile macular degeneration (Stargardt disease) market has been segmented into diagnosis, management, and end user. Based on the diagnosis, the market has been segregated into fluorescein angiography (FA), fundus autofluorescence (FAF), optical coherence tomography (OCT), and electroretinography (ERG). The FA segment accounted for a market value of USD 270.110 million in 2016. Based on management, the market has been segregated into magnifying spectacles, magnifiers, and reading telescopes. The global juvenile macular degeneration (Stargardt disease) market on the basis of end-user is divided into hospital & eye clinics, and research & academic institutes.


Key Players


The prominent players in the global juvenile macular degeneration (Stargardt disease) market are Astellas Pharma Inc (Japan), Sanofi (France), Acucela Inc (Japan), Alkeus Pharma (US), Copernicus Therapeutics (US), Ophthotech Corporation (US), Bayer AG (Germany), Oxford BioMedica PLC (UK), and Grupo Ferrer (Spain).


Some of the key strategies followed by the players operating in the global juvenile macular degeneration (Stargardt disease) market were innovation, product development, acquisition, mergers, and expansion.


Global Juvenile Macular Degeneration (Stargardt Disease) Market Share, by Region, 2016 (%)  Juvenile Macular Degeneration (Stargardt Disease) Market


Source: MRFR Analysis


Regional Analysis


The global juvenile macular degeneration (Stargardt disease) market, based on region, is divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.


Europe accounted for the significant share in the market for juvenile macular degeneration. Rising investment in research & development, well-developed healthcare infrastructure, and increasing healthcare funds are some of the factors responsible for boosting the growth of the market in this region. Europe held the most significant market share of 32.7 % in 2016.


Americas is estimated to be the second-largest market. This is attributed due to the well-developed technology, rising healthcare expenditure, and the presence of the leading players in the market.


Asia-Pacific is projected to be the fastest-growing market due to the rising aging population, increasing healthcare expenditure, and rapidly changing healthcare sector. In addition to this, improving healthcare facilities and rising economic growth is positively impacting the market growth in this region.


The market in the Middle East & Africa is expected to witness steady growth due to increasing investments in research & development, well-developed infrastructure, and advancement in technology.


Key Updates



  • In November 2017, Astellas Pharma Inc launched “Repatha” a human monoclonal antibody for the treatment of hypercholesterolemia.



  • In December 2017, Sanofi acquired Protein Science company in order to expand its product portfolio.



  • In January 2017, Acucela Inc received orphan drug approval for treatment of Stargardt disease. Hence this product approval will help the company to increase its revenue in the future as very few drugs are available for the treatment of Stargardt disease.


Market Segmentation


Global Juvenile Macular Degeneration (Stargardt Disease) Market, by Diagnosis



  • Fluorescein Angiography (FA)

  • Fundus Autofluorescence (FAF)

  • Optical Coherence Tomography (OCT)

  • Electroretinography (ERG)


Global Juvenile Macular Degeneration (Stargardt Disease) Market, by Management



  • Magnifying Spectacles

  • Magnifiers

  • Reading telescopes     


Global Juvenile Macular Degeneration (Stargardt Disease) Market, by End-User



  • Hospital & Eye Clinics

  • Research & Academic Institutes


Global Juvenile Macular Degeneration (Stargardt Disease) Market, by Region



  • Americas

    • North America

      • US

      • Canada



    • Latin America





  • Europe

    • Western Europe

      • Germany

      • UK

      • France

      • Italy

      • Spain

      • Rest of Western Europe



    • Eastern Europe





  • Asia-Pacific

    • China

    • Japan

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific





  • Middle East & Africa

    • Middle East

    • Africa




Available Additional Customizations


Intended Audience



  • Medical device manufacturers and distributors

  • Government research organizations

  • Hospitals and clinics

  • Regulatory agencies

  • Contract research organizations

  • Pharmaceutical companies

  • Medical research laboratories

Report Attribute/Metric Details
  Market Size   1.85 Billion
  CAGR   7.36%
  Base Year   2023
  Forecast Period   2024-2032
  Historical Data   2021
  Forecast Units   Value (USD Billion)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Diagnosis, Management, and End user
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Astellas Pharma Inc (Japan), Sanofi (France), Acucela Inc (Japan), Alkeus Pharma (US), Copernicus Therapeutics (US), Ophthotech Corporation (US), Bayer AG (Germany), Oxford BioMedica PLC (UK), and Grupo Ferrer (Spain).
  Key Market Opportunities   Innovation, Product Development, Acquisition, Mergers And Expansion
  Key Market Drivers   Increasing prevalence of eye disorder and technological advancements in juvenile macular degeneration


Frequently Asked Questions (FAQ) :

juvenile macular degeneration (stargardt disease) market projected to grow at approximately 6.70% CAGR during the assessment period (2023-2030).

The valuation of the global juvenile macular degeneration (stargardt disease) market is estimated to increase to USD 1.85 Billion by the end of 2032.

Increasing prevalence of eye disorder and technological advancements in juvenile macular degeneration are major tailwinds pushing the growth of the global juvenile macular degeneration (stargardt disease) market.

North America holds the largest share in the global juvenile macular degeneration (stargardt disease) market, followed by Europe and the Asia Pacific, respectively.

Alkeus Pharmaceuticals Inc. (U.S.), Acucela Inc. (U.S.), Astellas Pharma Inc. (Japan), Sanofi (France), ProQR Therapeutics NV (Netherland), Bayer HealthCare (Germany), Copernicus Therapeutics Inc. (U.S.), F. Hoffmann-La Roche (Switzerland), Grupo Ferrer Internacional SA (U.S.), Nemus Bioscience Inc. (U.S.), Iris Pharma (U.S.), Ophthotech Corp (U.S.), Adverum Biotechnologies (U.S.), Iconic Therapeutics (U.S.), PanOptica (U.S.), Neurotech Pharmaceuticals (U.S.), and RXi Pharmaceuticals (U.S.), are some of the top players operating in the global juvenile macular degeneration (stargardt disease) market.

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.